EUVIMEDEUVIMED entdecken
Open Access

Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors

Amy L Funk iD, Meghri Katerji iD, Marwa Afifi iD, Katherine Nyswaner, Carolyn C Woodroofe, Zoe C Edwards iD, Eric Lindberg iD, Knickole L Bergman iD, Nancy R Gough iD, Maxine R Rubin iD, Kamila Karpińska iD, Eleanor W Trotter und 15 weitere

Science Signaling · 11.02.2025 · 18 (873)

DOI: 10.1126/scisignal.ado2857 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Signaling, erschienen am 11.02.2025. Verfasst von Amy L Funk und 26 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute at Frederick, NIH, Frederick, MD 21702, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-myc, Tumor Suppressor Protein p53, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The worldwide annual frequency and lethality of head and neck squamous cell carcinoma (HNSCC) is not improving, and thus, new therapeutic approaches are needed. Approximately 70% of HNSCC cases have either amplification or overexpression of MAP3K13 , which encodes the kinase LZK. Here, we found that LZK is a therapeutic target in HNSCC and that small-molecule inhibition of its catalytic function decreased the viability of HNSCC cells with amplified MAP3K13 . Inhibition of LZK suppressed tumor growth in MAP3K13 -amplified xenografts derived from HNSCC patients. LZK stabilized the transcription factor c-MYC through its kinase activity and gain-of-function mutants of p53 in a kinase-independent manner. We designed a proteolysis-targeting chimera (PROTAC) that induced LZK degradation, leading to decreased abundance of both c-MYC and gain-of-function p53, and reduced the viability of HNSCC cells. Our findings demonstrate that LZK-targeted therapeutics, particularly PROTACs, may be effective in treating HNSCCs with MAP3K13 amplification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mycTumor Suppressor Protein p53Squamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsMAP Kinase Kinase KinasesProtein Kinase InhibitorsGain of Function MutationHumansAnimalsMiceCell Line, TumorProteolysisXenograft Model Antitumor AssaysCell ProliferationMice, Nude

Substanzen

Proto-Oncogene Proteins c-mycTumor Suppressor Protein p53MYC protein, humanTP53 protein, humanMAP Kinase Kinase KinasesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute at Frederick, NIH, Frederick, MD 21702, USA.
  • Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-4255, USA.
  • Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, NIH, Rockville, MD 20850, USA.
  • Cell Division Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK.
  • BioSerendipity, LLC, Elkridge, MD 21075, USA.
  • Laboratory of Molecular OncoSignalling, IMol Polish Academy of Sciences, Warsaw, Poland.

ORCID-Profile: Amy L Funk, Meghri Katerji, Marwa Afifi, Zoe C Edwards, Eric Lindberg, Knickole L Bergman, Nancy R Gough, Maxine R Rubin, Kamila Karpińska, Amy James, Baktiar O Karim, Ting-Chia Chang, Li Chen, Xin Xu, Ivan Ahel, Anna A Marusiak, Rolf E Swenson, Steven D Cappell, John Brognard

Förderung

  • NCI NIH HHS
  • Intramural NIH HHS

Zitieren

APA

Funk, A. L., Katerji, M., Afifi, M., Nyswaner, K., Woodroofe, C. C., Edwards, Z. C., Lindberg, E., Bergman, K. L., Gough, N. R., Rubin, M. R., Karpińska, K., Trotter, E. W., Dash, S., Ries, A. L., James, A., Robinson, C. M., Difilippantonio, S., Karim, B. O., Chang, T. C., …, & Brognard, J. (2025). Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors. Science Signaling, 18(873). https://doi.org/10.1126/scisignal.ado2857

Vancouver

Funk AL, Katerji M, Afifi M, Nyswaner K, Woodroofe CC, Edwards ZC, et al. Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors. Science Signaling. 2025;18(873). doi:10.1126/scisignal.ado2857

BibTeX
@article{Funk2025,
  author = {Funk, Amy L and Katerji, Meghri and Afifi, Marwa and Nyswaner, Katherine and Woodroofe, Carolyn C and Edwards, Zoe C and Lindberg, Eric and Bergman, Knickole L and Gough, Nancy R and Rubin, Maxine R and Karpińska, Kamila and Trotter, Eleanor W and Dash, Sweta and Ries, Amy L and James, Amy and Robinson, Christina M and Difilippantonio, Simone and Karim, Baktiar O and Chang, Ting-Chia and Chen, Li and Xu, Xin and Doroshow, James H and Ahel, Ivan and Marusiak, Anna A and Swenson, Rolf E and Cappell, Steven D and Brognard, John},
  title = {Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors},
  journal = {Science Signaling},
  year = {2025},
  volume = {18},
  number = {873},
  doi = {10.1126/scisignal.ado2857}
}
Kostenlos starten →